Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy

Shemonti Hasan; Onilia Zorio; B. Mark Keegan; Brian G. Weinshenker; Eoin P. Flanagan; W. Oliver Tobin; Orhun H. Kantarci; Michel Toledano; Sean J. Pittock; Sebastian Lopez-Chiriboga; Anastasia Zekeridou; Cristina Valencia-Sanchez

doi:10.1007/s00415-023-11933-6

Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy

Shemonti Hasan, Onilia Zorio, B. Mark Keegan, Brian G. Weinshenker, Eoin P. Flanagan, W. Oliver Tobin, Orhun H. Kantarci, Michel Toledano, Sean J. Pittock, Sebastian Lopez-Chiriboga, Anastasia Zekeridou, Cristina Valencia-Sanchez

Neurology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	4707-4712
Number of pages	6
Journal	Journal of Neurology
Volume	270
Issue number	10
DOIs	https://doi.org/10.1007/s00415-023-11933-6
State	Published - Oct 2023

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1007/s00415-023-11933-6

Cite this

Hasan, S., Zorio, O., Keegan, B. M., Weinshenker, B. G., Flanagan, E. P., Tobin, W. O., Kantarci, O. H., Toledano, M., Pittock, S. J., Lopez-Chiriboga, S., Zekeridou, A., & Valencia-Sanchez, C. (2023). Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy. Journal of Neurology, 270(10), 4707-4712. https://doi.org/10.1007/s00415-023-11933-6

Hasan, S, Zorio, O, Keegan, BM, Weinshenker, BG, Flanagan, EP , Tobin, WO , Kantarci, OH, Toledano, M, Pittock, SJ, Lopez-Chiriboga, S, Zekeridou, A & Valencia-Sanchez, C 2023, 'Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy', Journal of Neurology, vol. 270, no. 10, pp. 4707-4712. https://doi.org/10.1007/s00415-023-11933-6

@article{1dc9c7d532f64c03a84895370c653e0c,

title = "Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy",

author = "Shemonti Hasan and Onilia Zorio and Keegan, {B. Mark} and Weinshenker, {Brian G.} and Flanagan, {Eoin P.} and Tobin, {W. Oliver} and Kantarci, {Orhun H.} and Michel Toledano and Pittock, {Sean J.} and Sebastian Lopez-Chiriboga and Anastasia Zekeridou and Cristina Valencia-Sanchez",

note = "Funding Information: S. Hasan, O. Zorio, O.H. Kantarci, M. Toledano, and C. Valencia-Sanchez declare that they have no conflict of interest. B.M. Keegan is funded by the Applebaum Family and is a member of the Center for Multiple Sclerosis and Autoimmune Research Mayo Clinic, receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases, and is an Editorial Board member of Multiple Sclerosis and Related Disorders. B.G. Weinshenker reports consulting fees from CANbridge Pharmaceuticals, Horizon Pharmaceuticals, Roche/Genentech, and speaking fees from Mitsubishi Tanabe and Horizon Pharmaceuticals. He reports payment from MedImmune/VielaBio/Horizon for participation in the NMOSD adjudication committee for the inebilizumab clinical trial and from Alexion for participation in the NMOSD adjudication committee for the eculizumab clinical trial. He reports payment from UCB Biosciences for participation in the MOG-IgG associated disorders clinical trial adjudication committee. He received travel support from Mitsubishi Tanabe. He has a patent NMO-IgG for diagnosis of neuromyelitis optica with royalties received from RSR Ltd, Oxford University, and Hospices Civils de Lyon. E.P. Flanagan has served on advisory boards for Alexion, Genentech, UCB, and Horizon Therapeutics outside the submitted work; has a patent for DACH1-IgG as a biomarker of paraneoplastic autoimmunity pending; has received speaker honoraria from Pharmacy Times; has received royalties from UpToDate; was a site primary investigator in a randomized clinical trial on inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics; has received funding from the National Institutes of Health (Grant R01NS113828); is a member of the medical advisory board of the MOG project; and is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. W.O. Tobin has received research funding from Mallinckrodt Inc, the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and the National Institutes of Health (Grant R01NS113803 and R01NS121928) outside the submitted work. He has received honoraria from Neurology Live and has co-edited Mayo Clinic Cases in Neuroimmunology. S.J. Pittock reported grants, personal fees, and nonfinancial support from Alexion and MedImmune/Viela Bio/Horizon (all compensation is paid directly to the Mayo Clinic); grants from the National Institutes of Health, Grifols, NovelMed, and F. Hoffmann-LaRoche/Roche/Genentech (all compensation is paid directly to Mayo Clinic); consulting for Astellas (compensation to Mayo Clinic and personal compensation); personal fees from Sage Therapeutics, UCB, and F. Hoffmann-LaRoche/Roche/Genentech; and had patent #8,889,102 issued, patent #9,891,219B2 issued, and a patent for GFAP-IgG; Septin-5-IgG; MAP1B-IgG; Kelch-like protein 11; PDE10A pending. A.S. Lopez-Chiriboga has served on advisory boards for Genentech and Horizon Therapeutics. A. Zekeridou reported grants from Roche/Genentech outside the submitted work and has a patent for DACH1-IgG as biomarker of neurological autoimmunity pending and a patent for PDE10A-IgG as biomarker of neurological autoimmunity pending. ",

year = "2023",

month = oct,

doi = "10.1007/s00415-023-11933-6",

language = "English (US)",

volume = "270",

pages = "4707--4712",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "D. Steinkopff-Verlag",

number = "10",

}

TY - JOUR

T1 - Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy

AU - Hasan, Shemonti

AU - Zorio, Onilia

AU - Keegan, B. Mark

AU - Weinshenker, Brian G.

AU - Flanagan, Eoin P.

AU - Tobin, W. Oliver

AU - Kantarci, Orhun H.

AU - Toledano, Michel

AU - Pittock, Sean J.

AU - Lopez-Chiriboga, Sebastian

AU - Zekeridou, Anastasia

AU - Valencia-Sanchez, Cristina

N1 - Funding Information: S. Hasan, O. Zorio, O.H. Kantarci, M. Toledano, and C. Valencia-Sanchez declare that they have no conflict of interest. B.M. Keegan is funded by the Applebaum Family and is a member of the Center for Multiple Sclerosis and Autoimmune Research Mayo Clinic, receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases, and is an Editorial Board member of Multiple Sclerosis and Related Disorders. B.G. Weinshenker reports consulting fees from CANbridge Pharmaceuticals, Horizon Pharmaceuticals, Roche/Genentech, and speaking fees from Mitsubishi Tanabe and Horizon Pharmaceuticals. He reports payment from MedImmune/VielaBio/Horizon for participation in the NMOSD adjudication committee for the inebilizumab clinical trial and from Alexion for participation in the NMOSD adjudication committee for the eculizumab clinical trial. He reports payment from UCB Biosciences for participation in the MOG-IgG associated disorders clinical trial adjudication committee. He received travel support from Mitsubishi Tanabe. He has a patent NMO-IgG for diagnosis of neuromyelitis optica with royalties received from RSR Ltd, Oxford University, and Hospices Civils de Lyon. E.P. Flanagan has served on advisory boards for Alexion, Genentech, UCB, and Horizon Therapeutics outside the submitted work; has a patent for DACH1-IgG as a biomarker of paraneoplastic autoimmunity pending; has received speaker honoraria from Pharmacy Times; has received royalties from UpToDate; was a site primary investigator in a randomized clinical trial on inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics; has received funding from the National Institutes of Health (Grant R01NS113828); is a member of the medical advisory board of the MOG project; and is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. W.O. Tobin has received research funding from Mallinckrodt Inc, the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and the National Institutes of Health (Grant R01NS113803 and R01NS121928) outside the submitted work. He has received honoraria from Neurology Live and has co-edited Mayo Clinic Cases in Neuroimmunology. S.J. Pittock reported grants, personal fees, and nonfinancial support from Alexion and MedImmune/Viela Bio/Horizon (all compensation is paid directly to the Mayo Clinic); grants from the National Institutes of Health, Grifols, NovelMed, and F. Hoffmann-LaRoche/Roche/Genentech (all compensation is paid directly to Mayo Clinic); consulting for Astellas (compensation to Mayo Clinic and personal compensation); personal fees from Sage Therapeutics, UCB, and F. Hoffmann-LaRoche/Roche/Genentech; and had patent #8,889,102 issued, patent #9,891,219B2 issued, and a patent for GFAP-IgG; Septin-5-IgG; MAP1B-IgG; Kelch-like protein 11; PDE10A pending. A.S. Lopez-Chiriboga has served on advisory boards for Genentech and Horizon Therapeutics. A. Zekeridou reported grants from Roche/Genentech outside the submitted work and has a patent for DACH1-IgG as biomarker of neurological autoimmunity pending and a patent for PDE10A-IgG as biomarker of neurological autoimmunity pending.

PY - 2023/10

Y1 - 2023/10

UR - http://www.scopus.com/inward/record.url?scp=85168331837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168331837&partnerID=8YFLogxK

U2 - 10.1007/s00415-023-11933-6

DO - 10.1007/s00415-023-11933-6

M3 - Letter

C2 - 37597071

AN - SCOPUS:85168331837

SN - 0340-5354

VL - 270

SP - 4707

EP - 4712

JO - Journal of Neurology

JF - Journal of Neurology

IS - 10

ER -

Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this